An evaluation of rozanolixizumab-noli for the treatment of anti-AChR and anti-MuSK antibody-positive generalized myasthenia gravis
. (Source: Expert Opinion on Biological Therapy)
Source: Expert Opinion on Biological Therapy - December 15, 2023 Category: Drugs & Pharmacology Authors: Alexandria MaticNouf AlfaidiVera BrilThe Ellen & Martin Prosserman Centre for Neuromuscular Diseases, University Health Network, University of Toronto, Toronto, Ontario, Canada Source Type: research
Retracted: Effects of Plasma Exchange Combined with Immunoglobulin Therapy on Consciousness, Immune Function, and Prognosis in Patients with Myasthenia Gravis Crisis: A Prospective Randomized Test
Comput Math Methods Med. 2023 Dec 6;2023:9786520. doi: 10.1155/2023/9786520. eCollection 2023.ABSTRACT[This retracts the article DOI: 10.1155/2022/7796833.].PMID:38094453 | PMC:PMC10718707 | DOI:10.1155/2023/9786520 (Source: Computational and Mathematical Methods in Medicine)
Source: Computational and Mathematical Methods in Medicine - December 14, 2023 Category: Statistics Authors: Computational And Mathematical Methods In Medicine Source Type: research
The burden of myasthenia gravis – highlighting the impact on family planning and the role of social support
ConclusionThis study shows a significant impact of MG on family planning decisions, affecting both women and men, and often resulting in life-altering decisions such as voluntary childlessness due to MG. The significance of social support becomes evident as a vital factor, especially when navigating through the healthcare system. Tailored healthcare approaches, organized guidance and comprehensive support is needed to enable informed decision-making and offer assistance for MG patients.Clinical trial registrationhttps://clinicaltrials.gov/study/NCT03979521, Registered 7 June 2019 (retrospectively registered). (Source: Frontiers in Neurology)
Source: Frontiers in Neurology - December 14, 2023 Category: Neurology Source Type: research
Assessing the length of hospital stay for patients with myasthenia gravis based on the data mining MARS approach
Predicting the length of hospital stay for myasthenia gravis (MG) patients is challenging due to the complex pathogenesis, high clinical variability, and non-linear relationships between variables. Considering the management of MG during hospitalization, it is important to conduct a risk assessment to predict the length of hospital stay. The present study aimed to successfully predict the length of hospital stay for MG based on an expandable data mining technique, multivariate adaptive regression splines (MARS). Data from 196 MG patients' hospitalization were analyzed, and the MARS model was compared with classical multipl...
Source: Frontiers in Neurology - December 14, 2023 Category: Neurology Source Type: research
Zilucoplan: First Approval
This article summarises the milestones in the development of zilucoplan leading to this first approval for gMG. (Source: Drugs)
Source: Drugs - December 14, 2023 Category: Drugs & Pharmacology Source Type: research
Safe use of contrast media in myasthenia gravis: systematic review and updated European Society of Urogenital Radiology Contrast Media Safety Committee guidelines
ConclusionsThere is limited evidence on the relationship between CM and myasthenia gravis symptoms. In the vast majority of myasthenia gravis patients, CM are safe. Probably, in less than 5% of the patients, iodine-based CM administration may lead to increased severity of the symptoms within the first 24 h after administration.Clinical relevance statementBe aware that intravenous administration of iodine-based contrast media can lead to an increase of symptoms in patients with myasthenia gravis within the first 24 h. This can probably happen in less than 5% of the patients.Key Points• It is unclear whether modern con...
Source: European Radiology - December 14, 2023 Category: Radiology Source Type: research
Zilucoplan: First Approval
This article summarises the milestones in the development of zilucoplan leading to this first approval for gMG. (Source: Drugs)
Source: Drugs - December 14, 2023 Category: Drugs & Pharmacology Source Type: research
Spontaneously resolving late-onset ocular myasthenia related to COVID-19. A case report
We report a 77-year-old woman who developed right eyelid ptosis five days after COVID-19 infection. Positive serum anti-acetylcholine receptor antibodies allowed the diagnosis of myasthenia gravis. It should be noted that there were no significant decremental changes on 3 Hz repetitive motor nerve stimulation study, even for the affected orbicularis oculi muscle. Clinical and pathophysiological data suggest that inflammation during COVID-19 could trigger an overproduction of autoantibodies previously present in the body at a subclinical level. This is the first case of COVID-19 infection complicated by myasthenia gravis, t...
Source: Acta Myologica - December 13, 2023 Category: Neurology Authors: Cyprian Popescu Source Type: research
